DEUTSCHE BANK AG\ - ONCOCYTE CORP ownership

ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 61 filers reported holding ONCOCYTE CORP in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of ONCOCYTE CORP
ValueSharesWeighting
Q1 2023$11,997
-44.8%
33,890
-49.9%
0.00%
Q4 2022$21,722
-55.7%
67,6700.0%0.00%
Q3 2022$49,000
-19.7%
67,6700.0%0.00%
Q2 2022$61,000
-20.8%
67,670
+32.2%
0.00%
Q1 2022$77,000
-8.3%
51,195
+32.1%
0.00%
Q4 2021$84,000
-53.6%
38,744
-23.7%
0.00%
Q3 2021$181,000
-31.2%
50,808
+11.2%
0.00%
Q2 2021$263,000
+7.3%
45,698
-3.2%
0.00%
Q1 2021$245,000
+120.7%
47,197
+1.5%
0.00%
Q4 2020$111,000
+136.2%
46,496
+37.5%
0.00%
Q3 2020$47,000
+11.9%
33,827
+52.3%
0.00%
Q2 2020$42,000
+147.1%
22,207
+214.5%
0.00%
Q1 2020$17,000
+6.2%
7,062
-5.8%
0.00%
Q4 2019$16,000
+45.5%
7,494
+24.8%
0.00%
Q3 2019$11,000
-72.5%
6,007
-62.9%
0.00%
Q2 2019$40,000
-94.6%
16,173
-91.4%
0.00%
Q1 2019$744,000188,720
+6290566.7%
0.00%
Q3 2018$0
-100.0%
3
-99.9%
0.00%
Q2 2018$7,000
-30.0%
3,033
-40.0%
0.00%
Q1 2018$10,000
-74.4%
5,054
-40.3%
0.00%
Q4 2017$39,000
+39.3%
8,466
+126.4%
0.00%
Q3 2017$28,000
+33.3%
3,739
-9.6%
0.00%
Q2 2017$21,000
+425.0%
4,138
+419.2%
0.00%
Q1 2017$4,000797
+3365.2%
0.00%
Q4 2016$0
-100.0%
23
-99.0%
0.00%
Q3 2016$11,000
+22.2%
2,376
-16.5%
0.00%
Q2 2016$9,000
+50.0%
2,847
+61.0%
0.00%
Q1 2016$6,0001,7680.00%
Other shareholders
ONCOCYTE CORP shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 14,716,204$20,456,0001.61%
PURA VIDA INVESTMENTS, LLC 6,022,534$8,371,0000.43%
P.A.W. CAPITAL CORP 199,700$278,0000.30%
Penbrook Management LLC 229,425$319,0000.28%
PERKINS CAPITAL MANAGEMENT INC 39,725$55,0000.05%
GSA CAPITAL PARTNERS LLP 201,047$279,0000.05%
Private Wealth Partners, LLC 150,000$209,0000.02%
Phoenix Holdings Ltd. 317,138$426,0000.02%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 255,300$355,0000.01%
ETF MANAGERS GROUP, LLC 157,933$226,0000.01%
View complete list of ONCOCYTE CORP shareholders